RxDoctor Payments Data

Marvin Siegel, DO

Cardiovascular Disease · Phoenix, AZNPI 1588665608

Payments from drug & device makers

$654in general payments, 2019–2025

Across 40 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$184
  • Amgen$84
  • E.r. Squibb & Sons, L.L.C.$70
  • Sanofi-aventis U.S. LLC$68
  • Pfizer$56
  • AstraZeneca$31
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$654 in reported general payments places this provider in the 25th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$235,801
Medicare patients
745
Services billed
2,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban452$450,452
XareltoRivaroxaban140$164,539
Repatha SureclickEvolocumab194$149,229
EntrestoSacubitril/Valsartan128$133,396
FarxigaDapagliflozin Propanediol132$118,097
MultaqDronedarone Hcl25$31,998
JardianceEmpagliflozin32$27,638
Repatha SyringeEvolocumab31$22,867
BrilintaTicagrelor18$17,452
Praluent PenAlirocumab23$11,005
VascepaIcosapent Ethyl23$10,182
DapagliflozinDapagliflozin Propanediol15$7,216
Losartan Potassium699$6,538
Ranolazine ErRanolazine57$5,690
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$450,452452 claims
Johnson & JohnsonXarelto$184$164,539140 claims
AstraZenecaFarxiga, Brilinta$31$135,549150 claims
NovartisEntresto$19$133,396128 claims
Sanofi-aventis U.S. LLCMultaq$68$31,99825 claims
Boehringer IngelheimJardiance$19$27,63832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →